Document is current
Any future updates will be listed below
-
Authors
Spencer Chapman, Michael https://orcid.org/0000-0002-5320-8193
Mitchell, Emily
Yoshida, Kenichi
Williams, Nicholas https://orcid.org/0000-0003-3989-9167
Fabre, Margarete A.
Ranzoni, Anna Maria
Robinson, Philip S. https://orcid.org/0000-0002-6237-7159
Kregar, Lori D.
Wilk, Matthias https://orcid.org/0000-0001-5429-7143
Boettcher, Steffen https://orcid.org/0000-0001-9937-0957
Mahbubani, Krishnaa https://orcid.org/0000-0002-1327-2334
Saeb Parsy, Kourosh https://orcid.org/0000-0002-0633-3696
Gowers, Kate H. C.
Janes, Sam M. https://orcid.org/0000-0002-6634-5939
Ng, Stanley W. K.
Hoare, Matt https://orcid.org/0000-0001-5990-9604
Green, Anthony R.
Vassiliou, George S. https://orcid.org/0000-0003-4337-8022
Cvejic, Ana https://orcid.org/0000-0003-3204-9311
Manz, Markus G. https://orcid.org/0000-0002-4676-7931
Laurenti, Elisa https://orcid.org/0000-0002-9917-9092
Martincorena, Iñigo https://orcid.org/0000-0003-1122-4416
Stratton, Michael R. https://orcid.org/0000-0001-6035-153X
Nangalia, Jyoti https://orcid.org/0000-0001-7122-4608
Coorens, Tim H. H. https://orcid.org/0000-0002-5826-3554
Campbell, Peter J. https://orcid.org/0000-0002-3921-0510
- License Information
-
More Information
Article History
Received: 14 November 2023
Accepted: 19 November 2024
First Online: 15 January 2025
Competing interests
: P.J.C., M.R.S. and I.M. are co-founders, stock holders and consultants for Quotient Therapeutics Ltd. M.H. is a consultant for Quotient Therapeutics Ltd, AstraZeneca and Boston Scientific and has received unrestricted scientific grants from Pfizer. M.A.F. is a current employee and stockholder of AstraZeneca. A.M.R. is a senior editor at Nature Medicine, a Nature Portfolio journal. A.M.R. was not involved in the editorial handling of this Nature paper (journals within the Nature Portfolio are editorially independent). All other authors declare no competing interests.
